Patents by Inventor Neil R. Curtis

Neil R. Curtis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl amidines, compositions containing such compounds and methods of use
    Patent number: 6319944
    Abstract: Compounds represented by formula I: or a pharmaceutically acceptable salt or hydrate thereof, are disclosed. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: November 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, Brian Libby, Neil R. Curtis, Janusz Kulagowski
  • Pyrrolo-pyridine derivatives
    Patent number: 5622950
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 22, 1997
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
  • Pyrrolo-pyridine derivatives
    Patent number: 5576319
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia whilst manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: August 26, 1994
    Date of Patent: November 19, 1996
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill, Adrian L. Smith
  • Pyrrolo-pyridine derivatives
    Patent number: 5563150
    Abstract: A class of chemical compounds comprising a pyrrolo[2,3-b]pyridine moiety and a halo-substituted heterocyclic moiety, linked via the 3-position of the pyrrolo[2,3-b]pyridine moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.
    Type: Grant
    Filed: August 9, 1995
    Date of Patent: October 8, 1996
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson
  • Pyrrolo-pyridine derivatives
    Patent number: 5432177
    Abstract: A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: July 11, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Raymond Baker, Janusz J. Kulagowski, Neil R. Curtis, Paul D. Leeson, Mark P. Ridgill
  • Peptides useful as tachykinin agonists
    Patent number: 5331089
    Abstract: A class of monomeric or dimeric peptides containing a specific hexa- or heptapeptide unit in either linear or cyclic form are active tachykinin antagonists and are therefore useful in disease states in which these peptides have been implicated, such as allergic conditions, inflammation, migraine, arthritis and CNS disorders.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: July 19, 1994
    Assignee: Merck Sharpe & Dohme, Ltd.
    Inventors: Neil R. Curtis, Brian J. Williams